Praxis Precision Medicines (PRAX) reported a Q3 net loss Wednesday of $2.75 per diluted share, compared with a loss of $2.72 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.95.

Collaboration revenue for the quarter ended Sept. 30 was $302,000, down from $468,000 a year earlier.

Analysts surveyed by Capital IQ expected $300,000.

As of Sept. 30, the company said it had $411.2 million in cash, cash equivalents and marketable securities.

The company's shares were down 6.8% in premarket activity Wednesday.